Recent updates in urticaria.
Med Clin (Barc)
; 161(10): 435-444, 2023 11 24.
Article
em En, Es
| MEDLINE
| ID: mdl-37537021
ABSTRACT
Urticaria is a skin-condition characterized by sudden-onset pruritic wheals with/without angioedema. Urticaria can be acute or chronic. Chronic urticaria may be spontaneous or inducible, based on absence/presence of specific triggers. Chronic spontaneous urticaria is most frequent (â¼80%). Urticaria is primarily a mast-cell mediated histaminergic-disorder. Recently, other inflammatory cells and pro-inflammatory cytokines have been implicated. Deeper understanding has unmasked two endotypes - IgE-mediated type I autoimmunity/autoallergy and IgG-mediated type IIb autoimmunity. Current treatment recommendation involving second-generation H1-antihistamines, omalizumab and cyclosporine is effective in 60-80% patients. So, newer treatment options are being explored based on emerging targets. Despite being non-lethal, urticaria considerably impairs patient's quality-of-life and may be associated with extra-cutaneous comorbidities. Several "patient reported outcome measures" have been proposed to evaluate disease-activity, impact and control, for effective treatment modulation till complete disease control. This review discusses the current understanding about urticaria and its future directions, to facilitate optimum evidenced-based care.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Urticária
/
Angioedema
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
/
Es
Revista:
Med Clin (Barc)
Ano de publicação:
2023
Tipo de documento:
Article